UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?

Biology (Basel, Switzerland), 2020-04, Vol.9 (4), p.80

2020

Volltextzugriff (PDF)

Hypoxia Abrogates Tumor-Suppressive Activities of C/EBPδ in Pancreatic Cancer

International journal of molecular sciences, 2024-08, Vol.25 (17), p.9449

2024

Volltextzugriff (PDF)

Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion

PLoS biology, 2006-08, Vol.4 (8), p.e232-e232

2006

Volltextzugriff (PDF)

Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-α secretion

BMC cancer, 2020-12, Vol.20 (1), p.1183-1183, Article 1183

2020

Volltextzugriff (PDF)

Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer

International journal of molecular sciences, 2023-06, Vol.24 (13), p.10704

2023

Volltextzugriff (PDF)

ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer

Cancers, 2021-07, Vol.13 (13), p.3321

2021

Volltextzugriff (PDF)

C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC

International journal of molecular sciences, 2023-01, Vol.24 (2), p.1537

2023

Volltextzugriff (PDF)

Protease‐activated receptor‐1 contributes to renal injury and interstitial fibrosis during chronic obstructive nephropathy

Journal of cellular and molecular medicine, 2019-02, Vol.23 (2), p.1268-1279

2019

Volltextzugriff (PDF)

Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview

Pharmaceutics, 2022-02, Vol.14 (2), p.390

2022

Volltextzugriff (PDF)

Myeloid DNA methyltransferase3b deficiency aggravates pulmonary fibrosis by enhancing profibrotic macrophage activation

Respiratory research, 2022-06, Vol.23 (1), p.1-162, Article 162

2022

Volltextzugriff (PDF)

PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex

Scientific reports, 2015-09, Vol.5 (1), p.14534-14534, Article 14534

2015

Volltextzugriff (PDF)

Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice

Scientific reports, 2016-09, Vol.6 (1), p.33030-33030, Article 33030

2016

Volltextzugriff (PDF)

Factor Xa: at the crossroads between coagulation and signaling in physiology and disease

Trends in molecular medicine, 2008-10, Vol.14 (10), p.429-440

2008

Volltextzugriff (PDF)

Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis

Molecular medicine (Cambridge, Mass.), 2015-06, Vol.21 (1), p.576-583

2015

Volltextzugriff (PDF)

Non-Tumor CCAAT/Enhancer-Binding Protein Delta Potentiates Tumor Cell Extravasation and Pancreatic Cancer Metastasis Formation

Biomolecules (Basel, Switzerland), 2021-07, Vol.11 (8), p.1079

2021

Volltextzugriff (PDF)

Thrombin-mediated vasculogenic mimicry: important lessons to improve anticoagulant therapy of selected cancer patients

Signal transduction and targeted therapy, 2020-10, Vol.5 (1), p.253-253, Article 253

Spek, C Arnold

2020

Volltextzugriff (PDF)

Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner

Biomedicines, 2022-01, Vol.10 (2), p.219

2022

Volltextzugriff (PDF)

Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?

Journal of clinical medicine, 2019-09, Vol.8 (10), p.1547

2019

Volltextzugriff (PDF)

CEBPD Potentiates the Macrophage Inflammatory Response but CEBPD Knock-Out Macrophages Fail to Identify CEBPD-Dependent Pro-Inflammatory Transcriptional Programs

Cells (Basel, Switzerland), 2021-08, Vol.10 (9), p.2233

2021

Volltextzugriff (PDF)

Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma

Carcinogenesis (New York), 2019-03, Vol.40 (1), p.155-163

2019

Volltextzugriff (PDF)

Protease activated receptor 2 in diabetic nephropathy: a double edged sword

American journal of translational research, 2017-01, Vol.9 (10), p.4512-4520

2017

Volltextzugriff (PDF)

Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer

BMC cancer, 2017-02, Vol.17 (1), p.113-113, Article 113

2017

Volltextzugriff (PDF)

PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer

Oncotarget, 2018-08, Vol.9 (62), p.32010-32023

2018

Volltextzugriff (PDF)

Anticoagulant therapy of cancer patients: Will patient selection increase overall survival?

Thrombosis and haemostasis, 2015, Vol.114 (3), p.530-536

2015

Volltextzugriff (PDF)

Protease‐activated receptor 1 drives and maintains ductal cell fates in the premalignant pancreas and ductal adenocarcinoma

Molecular oncology, 2021-11, Vol.15 (11), p.3091-3108

2021

Volltextzugriff (PDF)

1 – 25 von 205

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(184)

Publikationsform

Sprache

Englisch
(205)
Japanisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?

Hypoxia Abrogates Tumor-Suppressive Activities of C/EBPδ in Pancreatic Cancer

Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion

Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-α secretion

Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer

ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer

C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC

Protease‐activated receptor‐1 contributes to renal injury and interstitial fibrosis during chronic obstructive nephropathy

Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview

Myeloid DNA methyltransferase3b deficiency aggravates pulmonary fibrosis by enhancing profibrotic macrophage activation

PAK2 is an effector of TSC1/2 signaling independent of mTOR and a potential therapeutic target for Tuberous Sclerosis Complex

Protease-activated receptor-1 deficiency protects against streptozotocin-induced diabetic nephropathy in mice

Factor Xa: at the crossroads between coagulation and signaling in physiology and disease

Pharmacological Targeting of Protease-Activated Receptor 2 Affords Protection from Bleomycin-Induced Pulmonary Fibrosis

Non-Tumor CCAAT/Enhancer-Binding Protein Delta Potentiates Tumor Cell Extravasation and Pancreatic Cancer Metastasis Formation

Thrombin-mediated vasculogenic mimicry: important lessons to improve anticoagulant therapy of selected cancer patients

Macrophage C/EBPδ Drives Gemcitabine, but Not 5-FU or Paclitaxel, Resistance of Pancreatic Cancer Cells in a Deoxycytidine-Dependent Manner

Immune Checkpoints as Promising Targets for the Treatment of Idiopathic Pulmonary Fibrosis?

CEBPD Potentiates the Macrophage Inflammatory Response but CEBPD Knock-Out Macrophages Fail to Identify CEBPD-Dependent Pro-Inflammatory Transcriptional Programs

Action and clinical significance of CCAAT/enhancer-binding protein delta in hepatocellular carcinoma

Protease activated receptor 2 in diabetic nephropathy: a double edged sword

Potential importance of protease activated receptor (PAR)-1 expression in the tumor stroma of non-small-cell lung cancer

PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer

Anticoagulant therapy of cancer patients: Will patient selection increase overall survival?

Protease‐activated receptor 1 drives and maintains ductal cell fates in the premalignant pancreas and ductal adenocarcinoma

Suchergebnisse filtern